Verizon Settles With YMax and 3 Dow Movers to Follow

Hewlett-Packard Company (NYSE:HPQ) and Lenovo (LNVGY) should experience better shipment performance than Acer and Asustek in January because of strong demand in China, says DigiTimes. Taiwan-based supply chain makers report that the majority of notebook vendors are expected to suffer from slumping performance in the first quarter.

Procter & Gamble Company’s (NYSE:PG) license agreement with Inter Parfums (NASDAQ:IPAR) terminates on April 3rd, but the latter has entered into a ten-year exclusive worldwide fragrance license to create, manufacture, and distribute perfumes and fragrance-related products under the Alfred Dunhill Limited brand in an accord that begins on the same date. The latter will assume production and distribution of the existing Alfred Dunhill fragrance collections with sales of current fragrances planned for Spring, and a new men’s scent is being readied for 2014.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Verizon Communications (NYSE:VZ) resolves all disputes with YMax Communications, a subsidiary of magicJack VocalTec Communications (NASDAQ:CALL), through the calendar year 2012, according to a regulatory filing. There will not be any future negative impact to the firm’s financial statements concerning this settlement.

Pfizer (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) said that the Ministry of Health, Labor and Welfare of Japan has cleared Eliquis for the prevention of ischemic stroke and systemic embolism in patients suffering from nonvalvular atrial fibrillation. The durg is a novel anticoagulant that has shown risk reductions compared to Warfarin in three important outcomes of stroke, major bleeding and all-cause death. Eliquis is an oral direct Factor Xa inhibitor, part of a novel therapeutic class. This marks the third approval for the drug for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, following approvals in the European Union and Canada. On September 26th, the FDA acknowledged receipt of the Eliquis New Drug Application resubmission to decrease the risk of stroke and systemic embolism in adult patients with NVAF. The agency has deemed the resubmission a complete response to its June 22nd Complete Response Letter that asked for additional information on data management and verification from the ARISTOTLE trial. The FDA Prescription Drug User Fee Act date is March 17th.

Investing Insights: Will Hewlett-Packard be the Turnaround Story of 2013?